[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Akero Therapeutics (AKRO) Form 4 shows Chief Scientific Officer Timothy Rolph used a Rule 10b5-1 plan to exercise 12,500 vested stock options at an exercise price of $28.35 and immediately sold those shares in multiple transactions on 10/07/2025. The sale comprised 11,463 shares at a weighted-average price of $46.013 and 1,037 shares at a weighted-average price of $46.822, leaving the reporting person with 166,571 shares beneficially owned and 49,945 options outstanding after the transactions. The filing cites a previously adopted Rule 10b5-1 trading plan dated 08/12/2024 and confirms the exercised options were vested and exercisable.

Positive

• 12,500 stock options were exercised at an exercise price of $28.35
• Options exercised were vested and currently exercisable, per the filing
• Transactions executed pursuant to a pre-existing Rule 10b5-1 trading plan dated 08/12/2024

Negative

• Reporting person disposed of 12,500 shares via sales on 10/07/2025, reducing holdings
• Sales occurred at weighted-average prices of $46.013 and $46.822, which may be viewed as insider liquidity

Insights

Insider Transactions Analyst

TL;DR: Insider exercised $28.35-strike options and sold the resulting shares under a Rule 10b5-1 plan on 10/07/2025.

The reporting person exercised 12,500 vested options at an exercise price of $28.35, creating 12,500 shares that were sold the same day in multiple trades at weighted-average prices of $46.013 and $46.822. After these transactions, beneficial ownership stood at 166,571 shares with 49,945 options remaining.

The transactions were effected under a Rule 10b5-1 trading plan dated 08/12/2024, which provides an affirmative defense for preplanned trades. Monitor future Form 4s for any change in cadence of sales or additional option exercises within the next 12 months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rolph Timothy

(Last) (First) (Middle)

601 GATEWAY BOULEVARD

SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2025		M(1)		12,500	A	$28.35	179,071	D
Common Stock	10/07/2025		S(1)		11,463	D	$46.013(2)	167,608	D
Common Stock	10/07/2025		S(1)		1,037	D	$46.822(3)	166,571	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$28.35	10/07/2025		M(1)			12,500	(4)	12/07/2030	Common Stock	12,500	$0	49,945	D

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2024, previously adopted by the Reporting Person.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.545 to $46.54, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.57 to $47.10, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

4. The options are vested and currently exercisable.

	/s/ Jonathan Young, Attorney-in-Fact	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Akero (AKRO) Form 4 filed by Timothy Rolph report?

The Form 4 reports the exercise of 12,500 vested options at $28.35 and the sale of those 12,500 shares on 10/07/2025 under a Rule 10b5-1 plan.

How many shares did Timothy Rolph own after the transactions in the Form 4?

After the reported transactions, the filing shows beneficial ownership of 166,571 shares and ownership of 49,945 outstanding options.

At what prices were the AKRO shares sold according to the Form 4?

Shares were sold in multiple transactions at weighted-average prices of $46.013 (range $45.545–$46.54) and $46.822 (range $46.57–$47.10), as disclosed in the filing.

Were the transactions part of a prearranged trading plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan dated 08/12/2024.

Are the exercised options still exercisable or restricted?

The filing explicitly states the options were vested and currently exercisable at the time of exercise.